Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Michael, Reusch"'
Autor:
Alexander Zarbock, Tobias E. Larsson, Nicolas Noiseux, C. David Mazer, Johannes Böhm, Maxime Laflamme, Klaus Matschke, Jan Burkert, Benoit de Varennes, Andrej Myjavec, Andreas Böning, Jay L. Koyner, Dan Engelman, Michael Reusch, Matthias Thielmann, Belén Adrio Nazar, Craig Brown, Cara East, Antonino Ginel Iglesias, Sven Helms, David Kress, Andre Lamy, C David Mazer, Guillermo Muniz Albaiceta, Ignacio Munoz Carvajal, Saturo Osaki, Guillermo Reyes Copa, Claudio Ronco, Vincent Scavo, Ryan Shelstad, Madhav Swaminathan, Gabor Szabo, Nicholas Teman, Jan Vojacek, Thorsten Wahlers
Publikováno v:
EClinicalMedicine, Vol 76, Iss , Pp 102830- (2024)
Summary: Background: Cardiac surgery invariably triggers acute kidney stress causing adverse renal outcomes. The AKITA study evaluated the efficacy and safety of RMC-035, a novel analogue of alpha-1-microglobulin, for reducing cardiac surgery-associa
Externí odkaz:
https://doaj.org/article/d2e8e64e8e384d22953ea64d281d6785
Autor:
Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca De Nicola, James Young, Nada Dimković, Michael Reusch
Publikováno v:
Advances in Therapy. 40:1546-1559
Introduction: This study was conducted to elucidate the safety of roxadustat, an oral medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis-dependent (ID-DD) chronic kidney disease (CKD). Methods: Safety results from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517a4dcc06ac9f3636632a0486db6f74
https://doi.org/10.1007/s12325-023-02433-0
https://doi.org/10.1007/s12325-023-02433-0
Autor:
Janine Topp, Matthias Augustin, Kathrin von Usslar, Ramona Gosau, Kristian Reich, Michael Reusch, Christine Blome
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 2, Pp 211-217 (2018)
This study investigated the validity and feasibility of the Patient Benefit Index 2.0 (PBI 2.0), a short instrument to assess patient-relevant treatment benefit. In a cross-sectional study, patients with skin diseases completed the PBI 2.0 alongside
Externí odkaz:
https://doaj.org/article/7428dbc1042945d2ae27d5a4090f2c07
Autor:
Yasir J. Sepah, Quan Dong Nguyen, Yusuke Yamaguchi, Tetsuro Otsuka, Yoshikatsu Majikawa, Michael Reusch, Tadao Akizawa
Publikováno v:
Kidney International Reports. 7:763-775
Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD).Conducted in Japan, CL-0307 (NCT02952092) and CL-310
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c3866faa9be592f927f528d9186281
https://doi.org/10.1016/j.ekir.2022.01.1045
https://doi.org/10.1016/j.ekir.2022.01.1045
Autor:
Ciro Esposito, Botond Csiky, Michael Schömig, Udaya Valluri, Jonathan Barratt, Władysław Sułowicz, Michael Reusch
Publikováno v:
Advances in Therapy
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40cdc163721c176d6781c7c9a05a060f
https://doi.org/10.1007/s12325-021-01904-6
https://doi.org/10.1007/s12325-021-01904-6
Autor:
Ciro Esposito, James Young, Michael Schömig, Michael Reusch, Botond Csiky, Władysław Sułowicz, Jonathan Barratt
Publikováno v:
Advances in Therapy
Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods Efficacy and safety results from four phase 3, randomized, op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1629264b42b7ac68110f3f0d77dac9ef
https://doi.org/10.1007/s12325-021-01903-7
https://doi.org/10.1007/s12325-021-01903-7
Publikováno v:
Kidney International Reports
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (ND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a861e6689271ef9dcda7394262c63ba
https://doi.org/10.1016/j.ekir.2021.04.003
https://doi.org/10.1016/j.ekir.2021.04.003
Autor:
Ciro Esposito, Avtandil Tataradze, Udaya Valluri, Władysław Sułowicz, Michael Reusch, Evgeny Shutov, Nada Dimkovic, Branislav Andric
Publikováno v:
Nephrology Dialysis Transplantation
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3, multicenter, randomized, double-blind, placebo-controlled study examined p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e034519810f9ac7c5b4915699daf0418
https://doi.org/10.1093/ndt/gfab057
https://doi.org/10.1093/ndt/gfab057
Autor:
Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca De Nicola, Michael Reusch, James Young, Nada Dimkovic
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Patients with late-stage chronic kidney disease (CKD) who are non–dialysis-dependent (NDD) or incident to dialysis (ID) (e.g. initiated dialysis within the last 4 months) or dialysis-dependent (DD) represent a vulnerable populat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a9466898808e19c77ff173004315874
https://doi.org/10.1093/ndt/gfac072.015
https://doi.org/10.1093/ndt/gfac072.015
Autor:
Markus Tiemann, Christian Hallermann, Michael Reusch, Thomas Loening, Igor B. Buchwalow, Volker Mielke, Werner Boecker, Ursula Reusch
Publikováno v:
The American Journal of Dermatopathology. 43:93-102
Extraocular sebaceous carcinoma (ESC) is a rare appendiceal skin tumor. In contrast to ocular sebaceous carcinoma, information about the exact cellular architecture of these lesions is scarce and the histogenesis of ESC is unknown. Here, we extend ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d0ba333c051c35cfa4be81e8455430
https://doi.org/10.1097/dad.0000000000001667
https://doi.org/10.1097/dad.0000000000001667